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Abstract 
 
Predicting response to neoadjuvant therapy is a vexing challenge in breast cancer. In 
this study, we evaluate the ability of deep learning to predict response to HER2-
targeted neo-adjuvant chemotherapy (NAC) from pre-treatment dynamic contrast-
enhanced (DCE) MRI acquired prior to treatment. In a retrospective study 
encompassing DCE-MRI data from a total of 157 HER2+ breast cancer patients from 
5 institutions, we developed and validated a deep learning approach for predicting 
pathological complete response (pCR) to HER2-targeted NAC prior to treatment. 100 
patients who received HER2-targeted neoadjuvant chemotherapy at a single 
institution were used to train (n=85) and tune (n=15) a convolutional neural network 
(CNN) to predict pCR. A multi-input CNN leveraging both pre-contrast and late post-
contrast DCE-MRI acquisitions was identified to achieve optimal response prediction 
within the validation set (AUC=0.93).  This model was then tested on two independent 
testing cohorts with pre-treatment DCE-MRI data: 28 patients who received HER2-
targeted NAC at a second institution and a 29-patient clinical trial dataset with imaging 
data from 3 institutions.  This model achieved strong performance in a 28 patient 
testing set from a second institution (AUC=0.85, 95% CI 0.67-1.0, p=.0008) and a 29 
patient multicenter trial including data from 3 additional institutions (AUC=0.77, 95% 
CI 0.58-0.97, p=0.006). Deep learning-based response prediction model was further 
found to exceed both a multivariable model incorporating predictive clinical variables 
(AUC < .65 in testing cohorts) and a model utilizing semi-quantitative DCE-MRI 
pharmacokinetic measurements (AUC < .60 in testing cohorts) in performance and 
robustness. The results presented in this work across multiple sites suggest that with 
further validation deep learning could provide an effective and reliable tool to guide 
targeted therapy in breast cancer, thus reducing overtreatment among HER2+ 
patients.   
1. Introduction 
 
Neoadjuvant chemotherapy (NAC), the administration of chemotherapy and other agents 
prior to surgery, constitutes the first avenue of intervention for an expanding portion of 
breast cancer patients (1). Given the physical (2) and financial (3) burden of treatment, it 
is desirable to identify which patients will respond to NAC as early as possible. However, 
there is currently a lack of clinically validated pre-treatment predictors of response in the 
neo-adjuvant setting. Predictive biomarkers of NAC response would provide immense 
clinical value by enabling the identification of patients who will benefit most from 
neoadjuvant intervention and help guide the choice of most effective NAC strategy from 
the inception of treatment.     
 
There has been increased interest in the use of analytic approaches to predict therapeutic 
response from standard clinical imaging, most frequently dynamic contrast-enhanced 
(DCE) MRI in the neoadjuvant setting. Radiomics-based approaches, involved the high-
throughput extraction and analysis of quantitative imaging features describing tumor 
texture and shape, has shown promise in assessment of response prior to (4–7) and 
during (8) treatment. More recently, deep learning has emerged as a promising tool for 
response prediction. Whereas radiomics approaches rely on explicitly defined algorithmic 
descriptors of imaging phenotypes, deep learning utilizes the training of a neural network 
to discover novel patterns best suited to perform tasks such as classification. Accordingly, 
studies entailing the training of a convolutional neural network (CNN), a type of neural 
network for the discovery of visual patterns in images, from DCE-MRI data have shown 
deep learning to be a powerful tool for breast cancer diagnosis (9–13), subtype 
classification (14), and diagnosis of metastasis (15) on DCE-MRI. Recently, some studies 
have shown the ability of deep learning approaches in predicting response before (16,17) 
and early (18,19) in NAC.   
 
Although promising, most previous studies (20) have explored response prediction 
among biologically and clinically heterogeneous breast cancers. Breast cancer is 
frequently clinically stratified into categories based on expression of hormone receptors 
(21), e.g. human epidermal receptor 2-positive (HER2+), hormone receptor-positive 
(HR+), and triple negative (TN). While many studies have grouped these tumor categories 
when exploring imaging markers of NAC response, there is likely substantial value in 
explicitly accounting for receptor status category in this context, given that 
responsiveness and standard-of-care treatment strategy varies considerably among 
these categories (3,22). For instance, HER2+ patients will receive HER2-targeted agents 
such as trastuzumab and/or pertuzumab in addition to standard chemotherapy agents, 
whereas triple negative patients will receive only chemotherapy. Several studies (4,6) 
have shown that tailoring computational imaging approaches to receptor status 
categories improves capability to predict response, and the value of category-specific 
response prediction has been shown to be higher in HER2+ breast cancers  (23).  
 
Despite evidence regarding the benefits of considering subtype and therapeutic approach 
(4,6,23), deep learning studies to date (16–19) have pooled breast cancers across 
receptor status categories with varying neoadjuvant intervention approaches. Thus, the 
value of deep learning to predict response to a specific treatment strategy, such as HER2-
targeted NAC, remains unexplored. Additionally, prior studies have both trained and 
tested a CNN with data from only a single institution (17) or within a clinical trial dataset 
with standardized acquisition protocol (16). However, deep learning faces challenges in 
generalizing to new sample populations and coping with unfamiliar sources of 
heterogeneity (24–26), potentially limiting the performance of deep learning models when 
evaluated within new institutions (25,27).   
 
In this work, we utilized a multiphase CNN for the prediction of response to HER2-targeted 
NAC from pre-treatment DCE-MRI. Unlike all previous deep learning studies and a 
majority of radiomics studies, we explored breast NAC response prediction among a 
cohort of patients who receive a specific targeted treatment strategy: HER2+.  We 
developed a deep learning model to identify pCR to HER2-targeted NAC from a cohort of 
pre-treatment DCE-MRIs acquired at a single institution. In the design and training of our 
model, we place an emphasis on maximizing generalizability through a lightweight, multi-
input convolutional network architecture design tailored to temporal DCE-MRI data, as 
well as through preprocessing and training strategies to reduce the impact of variability 
of MRI acquisition protocol. We then tested our model on the most diverse, external multi-
site dataset to date for validation of a DL approach for predicting response to NAC: 
comprised of patients from a second, external institution and from a clinical trial dataset 
collected across 3 institutions. Its performance was compared against models 
incorporating response-associated clinical variables and DCE-MRI semi-quantitative 
pharmacokinetics.  
 
2. Results  
2.1. Patient Characteristics  
We investigated a total of 157 patients with HER2+ breast cancer from 5 institutions who 
received DCE-MRI exams prior to targeted NAC. Pathologist assessment of excised 
surgical samples revealed that 76 patients achieved pCR, defined as the absence of 
invasive cancer within the breast and axillary lymph nodes (ypT0N0/is), while 87 had 
residual disease following NAC (non-pCR). Patients were divided for model development 
and testing based on institution, in order to allow assessment for generalizability across 
institutions. The training (D1, n=85) and internal validation (D2, n=15) cohorts – used to 
learn and optimize predictive models, respectively – were formed using patients from 
Institution 1. A first external testing set (D3, n=28) was comprised of patients from 
institution 2. A second testing set (D4, n=29) consisted of patients imaged and treated at 
Institution 3, Institution 4, or Institution 5 as part of the BrUOG 211B multicenter clinical 
trial (28–30). Patients in D1, D2, and the majority of patients in D3 received a targeted 
NAC regimen of docetaxel, carboplatin, trastuzumab, and pertuzumab (DCTP). Patients 
in D4, and five patients from D3, received a regimen of only docetaxel, carboplatin, and 
trastuzumab (DCT).  
 
 
Table 1. Clinical variables for the DCE-MRI datasets utilized. ER, estrogen receptor. PR, 
progesterone receptor. pCR, pathological complete response.  
 D1 (n=85) D2 (n=15) D3 (n=28) D4 (n=29) 
 
pCR 
(n=42) 
Non-pCR 
(n=43) P 
pCR 
(n=8) 
Non-pCR 
(n=7) P 
pCR 
(n=16) 
Non-pCR 
(n=12) P 
pCR 
(n=10) 
Non-pCR 
(n=19) P 
Longest diameter, mm 
4.1  
[1.5-10.5] 
4.7  
[1.6-16.4] 0.33 
3.7  
[1.2-8.2] 
4.2  
[1.8-8.5] 0.69 
5.3  
[1.3-12.2] 
4.2  
[2.1-11.0] 0.35    
Mean age, years 
51.4  
[28-77] 
48.8  
[28-77] 0.30 
50.5  
[38-76] 
58.4  
[38-73] 0.20 
47.9  
[31-73] 
47.4  
[23-65] 0.93 
46.2  
[32-63] 
51.3  
[42-68] 0.12 
ER Status (%) 
  0.0005   0.07      0.68 
Negative 
23 8  3 0  8 4 0.38 5 8  
Positive  
19 35  5 7  8 8  5 11  
PR Status (%) 
  0.007   0.45   0.23   0.37 
Negative 
27 15  5 3  9 4  7 10  
Positive  
15 28  3 4  7 8  3 9  
Clinical Stage 
  0.65   0.63   0.15   0.70 
I 
4 2  1 0  1 3  0 0  
II 
29 30  6 6  9 7  6 10  
III 
9 11  1 1  6 1  4 9  
IV 
0 0  0 0  0 1  0 0  
Lymph Node Status 
  0.45   0.05       
Negative 
22 26  3 1  N/A N/A  N/A N/A  
Positive 
20 17  5 6  N/A N/A  N/A N/A  
 
DCE-MRI exams consisted of one pre-contrast t1-weighted acquisition acquired prior to 
and then 3-6 acquisitions following injection of a gadolinium-based contrast agent. 148 
patients were imaged with a 1.5 Tesla (T) MRI scanner and 9 patients were imaged with 
a 3 T scanner.  
  
 
2.2. Predictive value of clinical variable and DCE-MRI pharmacokinetic 
models 
We evaluated the association of clinical variables available for all datasets (age, estrogen 
receptor (ER) status, progesterone receptor (PR) status, stage, and tumor size) and pCR 
in the training set. Of these, ER status (p=.0005) and PR status (p=0.007) were found to 
be individually significant and thus were incorporated into a multivariable clinical logistic 
regression model. This model identified pCR with AUC = 0.679 (95% CI: 0.45-0.87, 
p=0.19) within D2 (Figure 1a), but performance dropped when applied to different 
institutions AUC = 0.62 (95% CI: 0.44-0.77, p=0.26) for D3 (Figure 1b) and AUC=0.57 
(95% CI: 0.40-0.73, p=0.50) for D4 (Figure 1c). A second model incorporating all clinical 
variables regardless of individual significance exhibited greater drop off between 
institutions (AUC=0.66 for D2, AUC = 0.54 for D3, and AUC=0.53 for D4). 
 
 
We also evaluated whether a set of commonly evaluated semi-quantitative 
pharmacokinetic parameters, measuring temporal change in contrast enhancement on 
DCE-MRI, could help predict response to HER2-targeted NAC on the subset of patients 
with available DCE-MRI timing info (D1, n=61; D2, n=13; D3, n=22; D4, n=16). A set of 
48 statistics of 8 semi-quantitative pharmacokinetic parameters describing the tumor 
enhancement profile voxelwise and across the entire tumor were computed on DCE-MRI 
with manual annotations of the tumor boundary. Within D1 and D2, permutations of seven 
types of classifiers paired with three to eight PK features chosen by 6 feature selection 
algorithms were trained to predict pCR using this set of PK features. Of these, a linear 
discriminant analysis (LDA) classifier with 3 features chosen by t-test was selected as the 
optimal pharmacokinetic model (AUC=0.81, 95% CI: 0.55-1.0 in D2) and significantly 
distinguished pCR in D2 (p=.025). However, this model performed poorly in external 
testing, achieving an AUC of 0.52 (95% CI: 0.29-0.74, p=0.87) in D3 and 0.58 (95% CI: 
0.22-0.91, p=0.70) in D4 (Figure 1).  
 
 
Figure 1. Receiver operating characteristic curves for the deep learning (DL) and 
comparison models (MCM: multivariable clinical model, PK: pharmacokinetic model, 
DL+MCM: model combining clinical variables and DL predictions) in internal validation 
cohort D2 (a) and external testing cohorts D3 (b) and D4 (c).  
2.3. Performance of Deep Learning Model  
A multi-input network was designed to exploit the dynamic nature of DCE-MRI by 
separately learning discriminative features particular to each temporal phase of DCE-MRI 
acquisition (Figure 2). The network was comprised of up to four distinct branches of 
convolutional layers, which were trained to extract patterns of response within a 2D image 
of a particular phase of DCE-MRI.  Representations from each phase were then 
aggregated into a set of deep features, then these deep features were processed with a 
final set of dense operations summarizing the relationships between patterns at each 
phase. 
 
 
Figure 2. Convolutional Neural Network (CNN) architecture for the prediction of 
pathological complete response (pCR) from two DCE-MRI phases. The pre-contrast 
phase and a post-contrast phase were passed separately as inputs to their own 
convolutional branch of the two-input network. Each phase was operated on by a 
unique set of convolution-based operations and summarized into a set of deep 
features, which were then combined and processed to yield a final score indicating 
probability of response. 
 
Multiple input configurations of this deep model were explored to identify what temporal 
information was most informative in the prediction of pCR (Table 2). Among pairwise 
combinations of DCE-MRI phases, response was best predicted by a network 
incorporating the pre-contrast and 3rd post-contrast scans (Pre-3). This model achieved 
an AUC of 0.93 (p=.001, 95% CI=0.80-1.0) within the internal validation set D2 and was 
thus chosen as the final response prediction model. At a classification threshold of .5, 
accuracy was 86.7%, with a corresponding sensitivity of 75% and specificity of 100%.  A 
four-input model incorporating all DCE-MRI phases (depicted in Supplementary Figure 1) 
was also trained, but underperformed (Accuracy=87%, AUC=0.80) relative to the best 
two-input model, potentially due to increased parameterization within a training dataset 
of limited size.  
 
 
 
 
Table 2: AUC, sensitivity and specificity for each CNN input configuration within the 
internal validation dataset. Pre, pre-contrast phase. 1-3, first through third post-contrast 
phases.   
DCE-MRI Phase Inputs AUC Sensitivity (%) Specificity (%) 
Pre-1 0.77 84 68 
Pre-2 0.81 86 79 
Pre-3 0.93 95 88 
1-2 0.81 87 71 
1-3 0.83 90 72 
2-3 0.76 83 68 
Pre, 1, 2, and 3 0.80 90 72 
 
 
The optimal two-phase model (Pre-3) was applied to the external testing cohorts. 
Within D3, the model significantly identified pCR with an AUC of 0.85 (p<.0001, 95% CI 
0.70-1.0). At the operating point, accuracy was 86%, with a corresponding sensitivity of 
81% and specificity of 92%. Likewise, discrimination of response to NAC was significant 
in the multi-institutional D4 cohort, achieving an AUC of 0.77 (p=0.003, 95% CI 0.61-
0.91), accuracy of 79%, sensitivity of 70%, and specificity of 84%.  
 
To provide greater interpretability to the model, we utilized gradient class activation 
maps (Grad-CAM) with guided backpropogation (31) to identify those image features that 
saliently contributed to successful predictions of therapeutic outcomes (figure 3). 
Intriguingly, the activation maps seemed to emphasize the tumor margins, non-mass 
enhancement patterns, and the surrounding peri-tumoral tissue. This finding is consistent 
with previous radiomic findings showing the importance of the peri-tumoral region in 
radiomics studies exploring NAC response prediction (4,23). Supplementary figure 2 
depicts activation maps for a scan where CNN confidence was low, with differing 
activation between pre- and post-contrast scans.  
 
 
 
Figure 3. Model interpretability results leveraging guided Grad-CAM to identify regions 
contributing predictions of response (top, blue) and non-response (bottom, red). 
Activation maps emphasize irregular margins, heterogeneous enhancement, and the 
peri-tumoral region as contributing to response predictions.   
 
 
A subset analysis was performed to determine whether the model could provide 
predictive value complementary to IHC-based HER2+ molecular subtypes, coarsely 
associated with response to HER2-targeted NAC. Among ER/PR negative patients, who 
are hormone receptor negative and typically have elevated response to targeted therapy, 
the CNN successfully identified 3 of 3 patients in D3 and 6 of 8 patients in D4 who did not 
achieve pCR. Likewise, among the less-responsive ER/PR Positive subtype of cancers, 
the network identified 7 of 9 patients and 3 of 5 patients who achieved pCR in D3 and D4, 
respectively. Furthermore, the probabilistic output of the CNN differed significantly 
between pCR and non-pCR within both subtypes in D3 (ER/PR Negative, n=10, p=0.001; 
ER/PR Positive, n=18, p = 0.010) and ER/PR Negative in D4 (ER/PR Negative, n=13, 
p=0.048; ER/PR Positive, n=16, p = 0.070) by two-sided t-test. Full subset level 
accuracies within the testing sets are included in Supplementary Table 1.  
 
We additionally assessed the impact of various MRI acquisition parameter on our deep 
learning model. Although the number of 3 T scans in the testing cohorts was limited (8 
total across both cohorts), subset analysis by magnetic strength revealed that this 
minority group was not less accurately identified than patients who received a 1.5 T scan 
(Supplementary Table 2). Specifically, accuracy among patients receiving 3 T MRI was 
80.0% in D3 (83% for 1.5 T) and 100% for D4 (77% for 1.5 T). We also explored the 
association between CNN-predicted response probability and a number of continuous 
acquisition parameter values (pixel spacing, slice thickness, TR, TE, number of phase 
encoding steps, percent sampling, flip angle, and contrast agent bolus volume) across 
both testing cohorts for the subset of scans with these values included in their DICOM file 
meta-information (Table 3). All MRI acquisition parameters were found to not be 
significantly correlated with CNN predictions in both D3 and D4 (p>.05), with the exception 
of the number of phase encoding step, which had a significant association in D4 (r=0.45, 
p=0.041, N=21), but not D3 (r=0.29, p=0.147, N=27).   
 
Table 3. Spearman correlation between deep learning predictions and various DCE-
MRI acquisition parameters in testing sets for all patients with each parameter available 
in DICOM metadata.  
 D3 (n=28) D4 (n=29) 
 N r P N r P 
Pixel Spacing 27 0.1753 0.3817 29 -0.1980 0.3031 
Slice Thickness 27 0.0420 0.8353 29 0.2964 0.1185 
Repetition Time (TR) 27 0.1911 0.3397 29 0.0142 0.9418 
Echo Time (TE) 27 -0.0310 0.8782 29 0.1650 0.3923 
Number Of Phase Encoding Steps 27 0.2865 0.1474 21 0.4481 0.0417 
Percent Sampling 27 0.0505 0.8025 29 0.0942 0.6268 
Flip Angle 27 0.1469 0.4646 29 -0.0025 0.9897 
Contrast Bolus Volume 22 -0.1902 0.3965 28 -0.0673 0.7335 
Time since contrast agent injection, s 22 0.0113 0.9602 16 0.0860 0.7516 
 
 
When a multivariate model combining prediction of response from the deep learning 
model with discriminative clinical variables (ER and PR status) was trained based on CNN 
output scores within D2, performance was AUC=0.69 in D3 (95% CI: 0.50-0.86, p=0.085) 
and AUC=0.63 in D4 (95% CI: 0.47-0.78, p=0.18). Notably, predictions from the deep 
learning model were found to offer significant independent value in identifying pCR when 
accounting for other clinical variables. The deep learning model was found to be 
independently associated with pCR in D3 (p=0.002) and D4 (p=0.020) when evaluated in 
a multivariable setting, whereas included clinical variables were not (ER status: p=0.82 in 
D3 and p=0.55 in D4, PR status: p=0.86 in D3 and p=0.68 in D4).  
 
3. Discussion 
 
Neo-adjuvant therapy can substantially improve survival, enable the use of breast-
conserving surgery, and spare lymph node resection. Specifically, in the context of HER2-
positive breast cancer, the advent of HER2-targeted therapeutic regimens has drastically 
improved outcomes. However, a considerable portion of HER2+ patients will still 
ultimately fail to respond to chemotherapy, imposing unnecessary suffering and financial 
burden while delaying effective intervention. Thus, there is an unmet clinical need for 
predictive markers that can identify prior to treatment which patients will benefit from 
HER2-targeted NAC. 
 
A number of recent approaches (7,16,17,19,20,32) involving the use of both deep 
learning and radiomics for response prediction of NAC treated breast cancer patients 
have been evaluated. Whereas radiomics entails pre-defining a list of potentially 
predictive image features to be used in combination with a machine learning model, deep 
learning strategies leverage neural networks to determine the most predictive image 
representations (typically derived as a series of image convolutions) in order to optimally 
discriminate therapeutic outcomes. Ha et al. (17) trained and tested a VGG 16 (33) CNN 
for NAC response prediction from images of the first post-contrast phase of DCE-MRI 
exams, collected at a single institution. Ravichandran et al. (16) trained an AlexNet (34) 
CNN for response prediction within the ISPY1 clinical trial dataset, placing multiple DCE-
MRI phases within the channels reserved for RGB colors in the original model. Huynh et 
al. (19) utilized a pre-trained VGG CNN to extract features from a multi-channel input from 
a 64 patient single institution dataset. El Adoui et al. utilized a multi-input CNN to predict 
response based on pre-treatment and during-treatment MRI data acquired at a single 
institution. Each of these deep learning studies utilize cohorts containing heterogeneous 
receptor status categories and therapeutic strategies. Apart from deep learning based 
approaches, several recent studies have explored response prediction through radiomics 
approaches at the pre-treatment time point, which leverage high-dimensional lists of pre-
defined quantitative imaging features (4,6,7,35). Some of these radiomic-based studies 
(4,6) have shown that response prediction was improved when tailoring imaging 
signatures to subtype groups, suggesting that the imaging phenotype associated with 
response might vary with tumor biology and treatment approach. Specifically, among 
HER2+ breast cancers who received targeted therapy, a specialized radiomic signature 
was found to distinguish response-associated molecular subtypes and subsequently 
predict response (23). Conversely, a recent large radiomics study found that a subtype-
agnostic radiomic response signature performed more poorly among HER2+ patients  as 
compared to other subtypes (7). 
 
In this study, we sought to develop a generalizable deep learning approach for the non-
invasive prediction of benefit of a targeted neoadjuvant therapeutic regimen using only 
treatment-naïve dynamic MRI of breast cancer. We trained a convolutional neural network 
with MRI data from before and after injection of contrast agent from a single institution for 
the prediction of response to HER2-targeted NAC. Our approach performed strongly 
across institutions in identifying patients who would achieve a complete pathologic 
response. Furthermore, this deep learning model provided predictive value independent 
to response-associated sub-categories of HER2+ breast cancers; for instance, by reliably 
identifying responders among non-ER/PR Negative patients, who exhibit lower targeted 
NAC response rates despite being clinically HER2+.  
 
Our study differed from previous deep learning approaches for breast cancer response 
prediction in the following ways. First, in contrast to previous work, which has largely 
explored computational and machine learning approaches for the prediction of NAC 
response within a general breast cancer population (7,16,17,19,20,32), our work explores 
the use of a CNN to predict response to targeted NAC for HER2+ breast cancer patients.  
Despite the demonstrated promise of deep learning for pre-treatment NAC response 
prediction, it remains underexplored in the context of receptor status category or targeted 
treatment regimen: likely due in part to the need for large datasets for deep learning model 
training. As compared to approaches non-specific to subtype, our approach has the 
potential to more directly guide therapeutic strategy by informing the likely therapeutic 
outcome of a specific targeted treatment approach. Second, our model was shown to be 
relatively robust across scans and institutions, an important consideration in clinical 
deployment and translation of these approaches. Thus far, no previous work exploring 
DL-based response prediction that we are aware of has explicitly demonstrated 
generalizability across data from multiple different sites not included in training. Our model 
was trained using data from a single institution in a manner specifically to improve its 
generalizability, through strategies such as a lightweight convolutional network design to 
mitigate overfitting and augmentation approach intended to introduce heterogeneity likely 
found in a multi-site setting (e.g. variations of spatial resolution). We then validated our 
predictive model on pre-treatment MRI data from a second institution and a multi-center 
clinical trial dataset and found performance to perform consistently across scanners and 
imaging data from four new institutions.  As such, this is the most rigorous validation of a 
deep learning approach for breast cancer response prediction from imaging to date. 
Furthermore, we thoroughly interrogated the association of DL model predictions with 
magnetic strengths (Supplementary Table 2) and other MRI settings (Table 3), and found 
our model to be largely independent of acquisition parameters across both cohorts. Third, 
the deep learning strategy presented was tailored to the dynamic nature of DCE-MRI 
through a multi-input CNN architecture that can accept and process multiple temporal 
contrast phases in parallel. Previous approaches have restructured DCE-MRI data to 
accommodate computer vision techniques designed for natural images; for instance, by 
aggregating DCE-MRI phases into an image’s RGB channels of an input image (16,19) 
or by utilizing only one DCE-MRI temporal phase (17). However, such approaches might 
be limited in their ability to capture prognostic differences in tumor presentation 
throughout contrast enhancement (36,37) during a dynamic MRI exam. The multi-input 
network employed in our study learns discriminative features that are specific to each 
phase of DCE-MRI acquisition through separate convolutional branches to extract 
response-associated image patterns particular to the pre- or post-contrast presentations. 
The dense operations following these convolutional branches enable the identification of 
relationships between CNN-extracted representations of individual contrast phases in 
order to predict a patient’s ultimate therapeutic response. This CNN architecture was 
found to offer stronger performance and generalizability compared to a semi-quantitative 
pharmacokinetic model of direct measures of a tumor’s enhancement on DCE-MRI, 
previously shown to be associated with NAC outcomes and survival (37–43).  
 
 A further distinction of our approach relative to radiomics methods is the ability to 
discover novel patterns of response without a-priori definition of a set of quantitative 
image features and the spatial regions where they will be discriminative. The large 
majority of radiomics approaches require precise, often manually-defined contours of the 
tumor (44) for analysis. In contrast, deep learning can utilize courser annotations such as 
a box containing the tumor and discover the patterns and regions most critical to a 
classification task. To delve further into this advantage, we utilized gradient class 
activation maps (Grad-CAM) to identify the portions of images that drove the CNN’s 
predictions of therapeutic outcomes (figure 2). The CNN honed in on the tumor’s margin 
and the peri-tumoral region, consistent with prior findings exploring radiomics of the 
peritumoral region and parenchyma (4,23,45–48) for outcome prediction, particularly in 
HER2+ breast cancer (23). Conceivably, these attention maps could be utilized by 
radiologists and oncologists to better understand CNN guidance regarding targeted 
therapy.  
 
Our study did have its limitations. First, the size of our dataset is limited. Our emphasis 
on response prediction for a specific targeted therapeutic approach restricts the size of 
available imaging data in the NAC setting. This constraint might explain the inferior 
performance of a model containing all DCE-MRI phases as compared to two-phase 
model, which could be over-parameterized to our limited training dataset. Nevertheless, 
our study is among the largest investigating deep learning-based response prediction 
from breast MRI (16,17,19) and the largest study to investigate response prediction to a 
specialized treatment strategy or within specific molecular subtype categories 
(4,6,20,23,49).  Despite limitations posed by the size of our specialized cohort, the 
demonstration of strong response prediction among a number of external institutions 
unseen during training is strongly suggestive of its reproducibility. Second, our approach 
does require manual data preprocessing, in particular drawing a box indicating the tumor 
region-of-interest. While delineating these tumors manually would require the time of 
trained radiologists if clinically implemented, it is important to note that our deep learning 
approach’s requirement of only a box annotation would be significantly less cumbersome 
to implement and less prone to inter-reader variability than radiomics approaches that 
require delineation of precise tumor boundaries. Future work aimed at automating this 
step, potentially through a deep learning-based region proposal approach (50), could be 
a worthwhile direction for improving its efficiency. Third, while a unique strength of our 
work is consideration of a specific therapeutic strategy, it should be noted that the exact 
HER2-targeted NAC regimen utilized in the validation cohorts did vary. For instance, 
patients in D4 did not receive pertuzumab, but did receive the HER2-targeted agent 
trastuzumab. While performance remained strong despite differing HER2-targeted NAC 
regimens, future work is needed to more fully determine the extent to which the model is 
generalizable across HER2-targeted NAC strategies.  
 
In summary, we demonstrate that deep learning is a robust and effective strategy for 
response prediction from breast MRI before initiation of targeted therapy. By predicting 
outcomes to HER2-targeted NAC, our model could be feasibly utilized to more precisely 
target treatment among HER2+ breast cancers. Furthermore, the implications of imaging 
markers for response to HER2-targeted therapies has wide-reaching potential benefit 
beyond breast cancer. HER2-targetted therapies have increasingly shown benefit in other 
cancer domains, but with lower overall rates of response and, as a result, high need for 
predictive biomarkers (51). Future work could explore the use of a neural for response 
prediction in such domains, potentially through transfer learning using the current breast 
prediction model. 
 4. Methods and materials 
4.1 Datasets 
4.1.1 Training (D1) and Internal Validation (D2) 
A cohort of 100 patients received HER2-targeted NAC consisting of docetaxel, 
carboplatin, trastuzumab, and pertuzumab (DCTP) who received pre-treatment imaging 
were retrospectively identified. 50 patients achieved pCR, as defined as the complete 
absence of residual invasive disease within the breast and axillary lymph nodes 
(ypT0N0/is) on post-NAC surgical samples.  The remaining 50 patients had residual 
disease following NAC, and were considered non-pCR. 
 
Patients were divided randomly into an 85 patient training cohort (D1) and a 15 patient 
validation cohort (D2) for optimizing model architecture, inputs, and hyperparameters. 
Clinical variables and acquisition parameters for all cohorts are summarized in Table 1 
and Supplementary Table 1, respectively.  
 
4.1.2 Testing Cohort D3 
 
28 HER2+ patients who received DCE-MRI exams at Institution 2 between March 1st, 
2012 and May 15th, 2016 prior to targeted NAC, a subset of a retrospective cohort 
previously described in (4) and (23), formed the first external testing cohort D3. Of the 28 
patients, 16 achieved pCR on surgical specimen (ypT0N0/is), while 12 were non-pCR. 
The majority of patients received a HER2-targeted regimen of DCTP (n=23), while 5 
received only docetaxel, carboplatin, and trastuzumab (DCT). 
 
4.1.3 Testing Cohort D4 
 
29 patients obtained from the BrUOG 211B multicenter preoperative clinical trial 
(NCT00617942) formed the second external testing cohort D4. Patients were treated with 
DCT and imaged at one of three institutions between April 27, 2012, through September 
4, 2015: 1) Brown University Oncology Research Group participating hospitals, 
Providence, Rhode Island, 2) Yale Cancer Center, New Haven CT, or 3) City of Hope 
Comprehensive Cancer Center, Duarte, California. 10 patients achieved pCR 
(ypT0N0/is). 
  
 
 
Table 4. Acquisition parameters for T1-weighted for breast dynamic contrast-enhanced 
MRI. T, tesla; mm, millimeters; ms, milliseconds; TE, echo time; TR, repetition time 
 D1/D2 D3 D4 
 Institution 1 Institution 2 Institution 3 
Magnetic Strength    
1.5 T 99 23 26 
3 T 1 5 3 
Spatial Resolution, mm 0.905 [0.417-1.136] 0.766 [0.568-1.042] 0.712 [0.498-1.063] 
Slice Thickness, mm 1.169 [1.000-2.500] 1.332 [0.900-3.000] 1.890 [1.000-2.400] 
Repetition Time (TR), ms 4.978 [4.220-6.200] 5.065 [4.430-6.926] 5.229 [3.760-6.464] 
Echo Time (TE), ms 2.182 [1.590-3.200] 1.769 [1.380-3.389] 2.123 [1.430-3.108] 
Number of Phase Encoding Steps 299[144 -387] 312 [261-352] 294 [225-338] 
Percent Sampling 84.0 [80-100] 84.5 [75-121] 74.3 [60-100] 
Flip Angle 9.5 [8-15] 10.4 [10-12] 12.0 [10-15] 
Contrast Agent Bolus Volume 14.7 [7-20] 16.2 [11-30] 16.8 [9.7-36.0] 
Number of Post-Contrast Acquisitons 3.35 [3-5] 5.05 [4-6] 3.524 [2.000-5.000] 
Average Time Between Acquisitions, s  145 [67.0-211] 86.852 [66.0-105] 115.660 [27.800-219.752] 
Post-Contrast Scan Time, s 469 [268-631] 438 [331-628] 363.380 [120.000-659.255] 
 
4.2 Data preprocessing and preparation 
In this study, pre-treatment DCE-MRI volumes with pre-contrast and 3 or more post-
contrast phases were utilized to predict the response to neoadjuvant therapy. To eliminate 
the heterogeneous distribution of intensity throughout the breast on DCE-MR images due 
to inconsistent magnetic fields of the MRI machine, a bias-correction was applied to each 
volume. A rectangular volume of interest (VOI) containing the largest slice of the tumor 
was specified by an experienced radiologist with 7 years’ experience practicing in breast 
radiology (P.T.) on post-contrast DCE-MRI subtraction images while consulting radiology 
and pathology reports. The rectangular region was then expanded to all neighboring 
slices containing tumor enhancement. Each DCE-MRI phase volume for each patient was 
cropped to this expanded VOI to yield 3D sub-volumes containing the tumor volume 
(Supplementary Figure 2). In the external validation cohorts, exact tumor boundaries were 
previously manually delineated on several slices by two radiologists working in consensus 
(D.P. 25 years practicing experience and M.E. 6 years residency and fellowship training). 
To be consistent with annotation protocol applied to institution 1, rectangular bounding 
boxes containing these annotations were derived and used in this study. Processing with 
a CNN requires inputs with a consistent size, thus VOIs were zero-padded to yield a 
consistent input size of 156 x 156 x 3 pixels (Supplementary figure 3), with 3 adjacent 2D 
slices included as channels of the CNN input.  Each input was normalized relative to its 
maximum grayscale level, so that all inputs had values between 0 and 1. 
 
4.3 Multi-phase Convolutional Neural Network Architecture 
The model used was inspired by previous work exploring multi-input CNNs for the 
prediction of response based on multiple scans throughout treatment (18). In contrast to 
this approach, we instead utilized a similar multi-input architecture to process multiple 
DCE-MRI temporal phases (acquired on the same pre-treatment imaging exam date) as 
input, with each phase processed by a separate convolutional branch. A model utilizing 
two DCE-MRI phases is depicted in Figure 1. 
 
Each phase-specific branch of the neural network consists of four blocks of 2D 
convolution layers, each followed by a non-linear activation function and max pooling 
layer (with the exception of the first block, where max pooling was not used). 32 kernels 
were used for each convolutional layer inside the first and second blocks for each branch, 
and 64 for the third and fourth blocks. A constant filter size of 3x3 pixels was used 
throughout the network. A dropout layer was applied after every two convolutional blocks, 
in order to help prevent overfitting and thus increase model generalizability. Deep features 
from each branch were concatenated, then processed with a fully connected layer of 512 
units, followed by an activation function with dropout. A second dense layer with 2 units 
yields the final output of the network, a probabilistic value indicating likelihood of pCR, 
was obtained from a final fully connected layer with sigmoid activation. The output of this 
layer is given by:  𝜎 = 11 + 𝑒&' 
 
Where z is the sum of the m deep features from the penultimate layer, xi, multiplied with 
learned weights, wi, plus a learned bias term, B:  
 𝑧 = 	* 𝑤,𝑥, + 𝐵	/,01  
 
 
Multiple versions of the model with different input DCE-MRI phases were explored. A set 
of models that take two DCE-MRI phases as inputs were first explored. Models were 
trained using all possible phase combinations to identify the pair of DCE-MRI phases 
providing the best performance within the internal validation set. Therefore, six pairwise 
combinations were used to train the two-phase CNN. The full Keras summary of model 
layers and parameters is included as Supplementary Table 3.  
 
Based on the same architecture, we additionally evaluated an extended architecture that 
considers four phases of DCE-MRI at one time. Therefore, four parallel CNNs were used. 
Their outputs were then concatenated and then processed by the network to yield a final 
classification based on all DCE-MRI phases. Supplementary Fig. 1 illustrates the 
architecture of this model.  
 
4.4 Deep learning model training 
The weights of the deep network were randomly initialized (52), then updated directly 
based on the 85 patient training set in an iterative fashion across 80 training epochs. Data 
augmentation was applied to synthetically expand the training set and improve 
generalizability of the model (Supplementary Figure 4). Operations including rotations, 
flips, and translations applied randomly on every epoch to each slice separately to 
maximize training data. An additional augmentation strategy, random resizing, was 
applied to mitigate the effects of heterogeneous voxel resolution between scans.  
 
 
In addition to fine tuning the architecture and inputs of the network, it was additionally 
necessary to optimize the hyper-parameters that dictate how the model will be trained. A 
grid search was performed to assess a number of different hyper-parameter 
combinations, and the best configuration was determined based on performance within 
D2. The hyper-parameters and values assessed in this grid search, as well as the best-
performing model configuration, are included in Supplementary Table 4.  
 
The best-performing model was trained using a binary cross entropy loss function and 
the Stochastic Gradient Decent (SGD) (53) optimization function, with a learning rate of 
5x10-4. The deep neural network architecture and training was implemented in Python, 
using Keras 2.2.4 API with Tensorflow 1.9.0 backend (Python 3.5.2), utilizing the following 
hardware: 
• CPU: 16 cores, 2.10 GHz clock speed, 128 GB of RAM memory 
• 4 GPUs: Nvidia P100, 3584 CUDA cores, 10.6 TeraFLOPS, 16 GB of 
memory. 
 
 
4.5 Semi-quantitative pharmacokinetic model 
A set of 8 semi-quantitative pharmacokinetic (PK) parameters (description and formulae 
listed in Supplementary Table 5) were computed voxel-wise and summarized for each 
patient by computing their mean, median, standard deviation, skewness and kurtosis 
values across the tumor, yielding a total of 40 statistics characterizing the distribution of 
PK measurements across tumor voxels. Additionally, these 8 measures were computed 
for the entire tumor based on the average intra-tumoral intensity at each DCE-MRI 
phase.  In total, 48 features pertaining to PK measurements were considered and 
evaluated in the comparative model.  
 
To ensure a fair comparison against deep learning, a number of classification models 
were explored and optimized for response prediction from PK statistics. Within D1 via 
cross-validation, pharmacokinetic features were reduced to sets of three to eight top 
features using 6 different feature ranking strategies (t-test, Wilcoxon rank-sum test, 
entropy, Bhattacharyya distance (54), area under the ROC curve, minimum redundancy 
maximum relevance (55)) and used to train 7 different classifier models: linear 
discriminant analysis (LDA), quadratic discriminant analysis (QDA), diagonal LDA, 
diagonal QDA, logistic regression, support vector machine, and random forest of 100 
trees). For each classifier type, the best performing feature set was evaluated on D2. Of 
these, the best performing classifier was chosen as the optimal PK model. Optimal 
configurations of each classifier, along with their performance in D1 and D2, are 
included in Supplementary Table 6.  
 
4.6 Statistical Analysis 
The output of the deep learning model was a 0 to 1 probabilistic score, where 1 
corresponded to a high confidence prediction of pCR following NAC. Within the 
validation and testing cohorts, performance was assessed by area under the receiver 
operating characteristic curve (AUC), as well as the sensitivity, specificity, and accuracy 
corresponding to a threshold of .5. Significance of the AUC was computed in MedCalc 
statistical software (56) using the method of DeLong et al. (57) to calculate standard 
error. 95% confidence intervals for the ROC curve were computed by bootstrapping 
across 1,000 iterations. 
 
As a comparative strategy, multivariable clinical models were trained and evaluated 
incorporating clinical variables common to all datasets: age, estrogen receptor (ER) 
status, progesterone receptor (PR) status, stage, largest tumor diameter, and lymph 
node positivity. Each variable was individually assessed for significant differences 
between pCR and non-pCR by Wilcoxon rank sum test for continuous variables (age, 
largest diameter) and chi-squared test for discrete variables (ER status, PR status, 
stage, lymph node positivity) in D1. All variables found to be individually significant were 
included in a multivariable logistic regression model and assessed for their ability to 
predict response in the D2-D4. A multivariable model incorporating both significant 
clinical variables and prediction from the DL model was trained in D2 (due to overly 
confident predictions of the DL model among training data), to evaluate the collective 
performance of both clinical information and CNN predictions in the testing sets. Each 
variable was assessed for independent significance when considering the model’s other 
variables by t-test of its coefficient in the logistic regression model.  
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Supplementary Figure 1. Four input CNN for prediction of NAC response from 
dynamic MRI. A pre-contrast and three sequential post-contrast DCE-MRI volumes are 
processed separated by convolutional branches. Features from each input branch are 
concatenated and processed to yield a final response prediction 
 
 
  
Supplementary Figure 2. Gradient class activation map for misclassified non-pCR 
patient with low confidence prediction. Class activation is split between pCR and non-
pCR for pre- and post-contrast phases.  
 
 
  
Supplementary Table 1. Subset analysis of performance stratified by NAC outcome 
and hormone receptor status in validation and testing cohorts. HR, Hormone receptor. 
 
 D2 (n=15) D3 (n=28) D4 (n=29) 
 Non-pCR pCR Non-
pCR 
pCR Non-
pCR 
pCR 
HR - N/A 2/3 3/3 6/7 6/8 4/5 
HR + 7/7 4/5 8/9 7/9 10/11 3/5 
 
  
Supplementary Table 2. Subset analysis of performance stratified by NAC outcome 
and scanner magnetic strength in validation and testing cohorts. T, Tesla. 
 
 D3 (n=28) D4 (n=29) 
 Non-pCR pCR Non-pCR pCR 
1.5 T 9/9 11/14 13/16 7/10 
3 T 2/3 2/2 3/3 N/A 
 
  
  
 
Supplementary Figure 3: Data preprocessing: each DCE-MRI temporal volume is 
cropped to the volume of interest (VOI) and zero-padded to a size of AAAxBBB, the 
input dimensions of the CNN.  
  
Supplemental Table 3. Full network architecture and all parameters for the two input deep 
learning model, obtained using model.summary() in Keras.  
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________ 
Layer (type)                      Output Shape           Param #      Connected to                      
================================================================================================== 
INPUT_DCEMRI_PRE (InputLayer)    (None, 156, 156, 3)   0                                             
__________________________________________________________________________________________________ 
INPUT_DCEMRI_POST (InputLayer)   (None, 156, 156, 3)   0                                             
__________________________________________________________________________________________________ 
conv2d_1 (Conv2D)                 (None, 154, 154, 32)  896           INPUT_DCEMRI_PRE[0][0]            
__________________________________________________________________________________________________ 
conv2d_2 (Conv2D)                 (None, 154, 154, 32)  896           INPUT_DCEMRI_POST[0][0]           
__________________________________________________________________________________________________ 
max_pooling2d_1 (MaxPooling2D)   (None, 77, 77, 32)     0             conv2d_1[0][0]                    
__________________________________________________________________________________________________ 
max_pooling2d_2 (MaxPooling2D)   (None, 77, 77, 32)     0             conv2d_2[0][0]                    
__________________________________________________________________________________________________ 
conv2d_3 (Conv2D)                 (None, 75, 75, 32)     9248         max_pooling2d_1[0][0]             
__________________________________________________________________________________________________ 
conv2d_4 (Conv2D)                 (None, 75, 75, 32)     9248         max_pooling2d_2[0][0]             
__________________________________________________________________________________________________ 
max_pooling2d_3 (MaxPooling2D)   (None, 37, 37, 32)     0             conv2d_3[0][0]                    
__________________________________________________________________________________________________ 
max_pooling2d_4 (MaxPooling2D)   (None, 37, 37, 32)     0             conv2d_4[0][0]                    
__________________________________________________________________________________________________ 
dropout_1 (Dropout)               (None, 37, 37, 32)     0             max_pooling2d_3[0][0]             
__________________________________________________________________________________________________ 
dropout_2 (Dropout)               (None, 37, 37, 32)     0             max_pooling2d_4[0][0]             
__________________________________________________________________________________________________ 
conv2d_5 (Conv2D)                 (None, 35, 35, 64)     18496        dropout_1[0][0]                   
__________________________________________________________________________________________________ 
conv2d_6 (Conv2D)                 (None, 35, 35, 64)     18496        dropout_2[0][0]                   
__________________________________________________________________________________________________ 
max_pooling2d_5 (MaxPooling2D)   (None, 17, 17, 64)     0             conv2d_5[0][0]                    
__________________________________________________________________________________________________ 
max_pooling2d_6 (MaxPooling2D)   (None, 17, 17, 64)     0             conv2d_6[0][0]                    
__________________________________________________________________________________________________ 
conv2d_7 (Conv2D)                 (None, 15, 15, 64)     36928        max_pooling2d_5[0][0]             
__________________________________________________________________________________________________ 
conv2d_8 (Conv2D)                 (None, 15, 15, 64)     36928        max_pooling2d_6[0][0]             
__________________________________________________________________________________________________ 
max_pooling2d_7 (MaxPooling2D)   (None, 7, 7, 64)       0             conv2d_7[0][0]                    
__________________________________________________________________________________________________ 
max_pooling2d_8 (MaxPooling2D)   (None, 7, 7, 64)       0             conv2d_8[0][0]                    
__________________________________________________________________________________________________ 
dropout_3 (Dropout)               (None, 7, 7, 64)       0             max_pooling2d_7[0][0]             
__________________________________________________________________________________________________ 
dropout_4 (Dropout)               (None, 7, 7, 64)       0            max_pooling2d_8[0][0]             
__________________________________________________________________________________________________ 
flatten_1 (Flatten)               (None, 3136)           0             dropout_3[0][0]                   
__________________________________________________________________________________________________ 
flatten_2 (Flatten)               (None, 3136)           0             dropout_4[0][0]                   
__________________________________________________________________________________________________ 
concatenate_1 (Concatenate)      (None, 6272)           0             flatten_1[0][0]                   
                                                                      flatten_2[0][0]                   
__________________________________________________________________________________________________ 
dense_1 (Dense)                   (None, 512)            3211776      concatenate_1[0][0]               
__________________________________________________________________________________________________ 
dropout_5 (Dropout)               (None, 512)            0             dense_1[0][0]                     
__________________________________________________________________________________________________ 
dense_2 (Dense)                   (None, 2)              1026         dropout_5[0][0]                   
================================================================================================== 
Total params: 3,343,938 
Trainable params: 3,343,938 
Non-trainable params: 0 
__________________________________________________________________________________________________ 
  
 Supplementary Figure 4: Data augmentation based on random rotations, horizontal 
and vertical flips, zoom and translations 
 
 
  
 
Supplementary Table 4: Tested and optimal values of the training parameters 
Parameter Tested values Optimal value 
 
Learning rate (lr) 0.05, 0.005, 0.0005, 0.00005 0.00005 
Batch size 2, 4, 8, 16, 32 8 
Momentum rate 0.8, 0.9, 0.99 0.99 
Weight initialization Normal, Uniform, Glorot Normal 
Per‐parameter adaptive learning 
rate methods 
Stochastic gradient descent 
(SGD), RMSprop, Adagrad, 
Adadelta, Adam 
SGD 
Learning rate decay Yes, no Yes (1e-6 per epoch) 
Activation function Sigmoid, ReLU, elu ReLU 
Dropout rate 0.1, 0.25, 0.3, 0.5, 0.75 0.25 (blocks 1 and 2) 
 0.30 (blocks 3 and 4) 
0.40 (dense layer) 
 
  
 
Supplementary Table 5. Features computed for the semiquantitative pharmacokinetic 
model. S0, S1, Sfinal, and Speak are the MRI signal intensity values on the pre-contrast 
phase, first post-contrast phase, final post-contrast phase, and post-contrast phase of 
maximum intensity. t0, t1, tfinal, and tpeak are the corresponding times at which those 
acquisitions were collected.  
 
Variable Description Formula 
Time-to-Peak Time in seconds of scan exhibiting peak 
intensity due to contrast enhancement 
throughout DCE-MRI exam 
tpeak - t0 
Maximum Percent 
Enhancement 
Percent intensity increase between max 
post-contrast and pre-contrast phase 
Speak/S0 
Early Percent 
Enhancement 
Percent intensity increase between first 
post-contrast and pre-contrast phase 
S1/S0 
Late Percent 
Enhancement 
Percent intensity increase between final 
post-contrast and pre-contrast phase 
Sfinal/S0 
Signal 
Enhancement 
Ratio 
Ratio of intensity increase of first post 
contrast phase to peak intensity increase, 
relative to pre-contrast phase 
(S1-S0)/(Speak-S0) 
Final Phase 
Enhancement 
Ratio  
Ratio of intensity increase of first post 
contrast phase to final intensity increase, 
relative to pre-contrast phase 
(S1-S0)/(Sfinal-S0) 
Rate of Uptake Rate of enhancement between peak 
enhancement and pre-contrast phase 
(Speak-S0)/(tpeak-t0) 
Rate of Washout Rate of intensity decay between peak 
enhancement phase and final DCE-MRI 
acquisition 
(Sfinal-Speak)/(tfinal-tpeak) 
 
 
  
Supplementary Table 6. Configurations and associated performance of optimal 
classification models incorporating statistics of voxelwise PK measures. For each 
classifier, the best performing number of features and feature selection scheme was 
chosen based on performance in cross-validation (D1), then that configuration was 
applied to D2. An LDA classifier with 3 features selected by t-test was chosen as the final 
PK classifier. 
 
 No. Features Feature 
Selection 
Algorithm  
D1 D2 
LDA 3 t-test 0.634 0.810 
QDA 8 t-test 0.547 0.738 
DLDA 3 t-test 0.638 0.762 
DQDA 3 t-test 0.581 0.762 
Logistic 
Regression 
3 wilcoxon 0.634 0.667 
SVM 3 t-test 0.623 0.762 
Random 
Forest 
7  wilcoxon 0.639 0.750 
 
 
 
